PDE5 inhibitor efficacy is estrogen dependent in female heart disease

Hideyuki Sasaki, Takahiro Nagayama, Robert M. Blanton, Kinya Seo, Manling Zhang, Guangshuo Zhu, Dong Lee, Djahida Bedja, Steven Hsu, Osamu Tsukamoto, Seiji Takashima, Masafumi Kitakaze, Michael E. Mendelsohn, Richard H. Karas, David A Kass, Eiki Takimoto

Research output: Contribution to journalArticle

Abstract

Inhibition of cGMP-specific phosphodiesterase 5 (PDE5) ameliorates pathological cardiac remodeling and has been gaining attention as a potential therapy for heart failure. Despite promising results in males, the efficacy of the PDE5 inhibitor sildenafil in female cardiac pathologies has not been determined and might be affected by estrogen levels, given the hormone's involvement in cGMP synthesis. Here, we determined that the heart-protective effect of sildenafil in female mice depends on the presence of estrogen via a mechanism that involves myocyte eNOS-dependent cGMP synthesis and the cGMP-dependent protein kinase Iα (PKGIα). Sildenafil treatment failed to exert antiremodeling properties in female pathological hearts from Gαq-overexpressing or pressure-overloaded mice after ovary removal; however, estrogen replacement restored the effectiveness of sildenafil in these animals. In females, sildenafil-elicited myocardial PKG activity required estrogen, which stimulated tonic cardiomyocyte cGMP synthesis via an eNOS/soluble guanylate cyclase pathway. In contrast, eNOS activation, cGMP synthesis, and sildenafil efficacy were not estrogen dependent in male hearts. Estrogen and sildenafil had no impact on pressure-overloaded hearts from animals expressing dysfunctional PKGIα, indicating that PKGIα mediates antiremodeling effects. These results support the importance of sex differences in the use of PDE5 inhibitors for treating heart disease and the critical role of estrogen status when these agents are used in females.

Original languageEnglish (US)
Pages (from-to)2464-2471
Number of pages8
JournalJournal of Clinical Investigation
Volume124
Issue number6
DOIs
StatePublished - Jun 2 2014

Fingerprint

Phosphodiesterase 5 Inhibitors
Heart Diseases
Estrogens
Cyclic GMP-Dependent Protein Kinase Type I
Type 5 Cyclic Nucleotide Phosphodiesterases
Pressure
Estrogen Replacement Therapy
Sildenafil Citrate
Cardiac Myocytes
Sex Characteristics
Muscle Cells
Ovary
Heart Failure
Hormones
Pathology
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sasaki, H., Nagayama, T., Blanton, R. M., Seo, K., Zhang, M., Zhu, G., ... Takimoto, E. (2014). PDE5 inhibitor efficacy is estrogen dependent in female heart disease. Journal of Clinical Investigation, 124(6), 2464-2471. https://doi.org/10.1172/JCI70731

PDE5 inhibitor efficacy is estrogen dependent in female heart disease. / Sasaki, Hideyuki; Nagayama, Takahiro; Blanton, Robert M.; Seo, Kinya; Zhang, Manling; Zhu, Guangshuo; Lee, Dong; Bedja, Djahida; Hsu, Steven; Tsukamoto, Osamu; Takashima, Seiji; Kitakaze, Masafumi; Mendelsohn, Michael E.; Karas, Richard H.; Kass, David A; Takimoto, Eiki.

In: Journal of Clinical Investigation, Vol. 124, No. 6, 02.06.2014, p. 2464-2471.

Research output: Contribution to journalArticle

Sasaki, H, Nagayama, T, Blanton, RM, Seo, K, Zhang, M, Zhu, G, Lee, D, Bedja, D, Hsu, S, Tsukamoto, O, Takashima, S, Kitakaze, M, Mendelsohn, ME, Karas, RH, Kass, DA & Takimoto, E 2014, 'PDE5 inhibitor efficacy is estrogen dependent in female heart disease', Journal of Clinical Investigation, vol. 124, no. 6, pp. 2464-2471. https://doi.org/10.1172/JCI70731
Sasaki H, Nagayama T, Blanton RM, Seo K, Zhang M, Zhu G et al. PDE5 inhibitor efficacy is estrogen dependent in female heart disease. Journal of Clinical Investigation. 2014 Jun 2;124(6):2464-2471. https://doi.org/10.1172/JCI70731
Sasaki, Hideyuki ; Nagayama, Takahiro ; Blanton, Robert M. ; Seo, Kinya ; Zhang, Manling ; Zhu, Guangshuo ; Lee, Dong ; Bedja, Djahida ; Hsu, Steven ; Tsukamoto, Osamu ; Takashima, Seiji ; Kitakaze, Masafumi ; Mendelsohn, Michael E. ; Karas, Richard H. ; Kass, David A ; Takimoto, Eiki. / PDE5 inhibitor efficacy is estrogen dependent in female heart disease. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 6. pp. 2464-2471.
@article{dab180454e1d4219acaf1e540b0bf025,
title = "PDE5 inhibitor efficacy is estrogen dependent in female heart disease",
abstract = "Inhibition of cGMP-specific phosphodiesterase 5 (PDE5) ameliorates pathological cardiac remodeling and has been gaining attention as a potential therapy for heart failure. Despite promising results in males, the efficacy of the PDE5 inhibitor sildenafil in female cardiac pathologies has not been determined and might be affected by estrogen levels, given the hormone's involvement in cGMP synthesis. Here, we determined that the heart-protective effect of sildenafil in female mice depends on the presence of estrogen via a mechanism that involves myocyte eNOS-dependent cGMP synthesis and the cGMP-dependent protein kinase Iα (PKGIα). Sildenafil treatment failed to exert antiremodeling properties in female pathological hearts from Gαq-overexpressing or pressure-overloaded mice after ovary removal; however, estrogen replacement restored the effectiveness of sildenafil in these animals. In females, sildenafil-elicited myocardial PKG activity required estrogen, which stimulated tonic cardiomyocyte cGMP synthesis via an eNOS/soluble guanylate cyclase pathway. In contrast, eNOS activation, cGMP synthesis, and sildenafil efficacy were not estrogen dependent in male hearts. Estrogen and sildenafil had no impact on pressure-overloaded hearts from animals expressing dysfunctional PKGIα, indicating that PKGIα mediates antiremodeling effects. These results support the importance of sex differences in the use of PDE5 inhibitors for treating heart disease and the critical role of estrogen status when these agents are used in females.",
author = "Hideyuki Sasaki and Takahiro Nagayama and Blanton, {Robert M.} and Kinya Seo and Manling Zhang and Guangshuo Zhu and Dong Lee and Djahida Bedja and Steven Hsu and Osamu Tsukamoto and Seiji Takashima and Masafumi Kitakaze and Mendelsohn, {Michael E.} and Karas, {Richard H.} and Kass, {David A} and Eiki Takimoto",
year = "2014",
month = "6",
day = "2",
doi = "10.1172/JCI70731",
language = "English (US)",
volume = "124",
pages = "2464--2471",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - PDE5 inhibitor efficacy is estrogen dependent in female heart disease

AU - Sasaki, Hideyuki

AU - Nagayama, Takahiro

AU - Blanton, Robert M.

AU - Seo, Kinya

AU - Zhang, Manling

AU - Zhu, Guangshuo

AU - Lee, Dong

AU - Bedja, Djahida

AU - Hsu, Steven

AU - Tsukamoto, Osamu

AU - Takashima, Seiji

AU - Kitakaze, Masafumi

AU - Mendelsohn, Michael E.

AU - Karas, Richard H.

AU - Kass, David A

AU - Takimoto, Eiki

PY - 2014/6/2

Y1 - 2014/6/2

N2 - Inhibition of cGMP-specific phosphodiesterase 5 (PDE5) ameliorates pathological cardiac remodeling and has been gaining attention as a potential therapy for heart failure. Despite promising results in males, the efficacy of the PDE5 inhibitor sildenafil in female cardiac pathologies has not been determined and might be affected by estrogen levels, given the hormone's involvement in cGMP synthesis. Here, we determined that the heart-protective effect of sildenafil in female mice depends on the presence of estrogen via a mechanism that involves myocyte eNOS-dependent cGMP synthesis and the cGMP-dependent protein kinase Iα (PKGIα). Sildenafil treatment failed to exert antiremodeling properties in female pathological hearts from Gαq-overexpressing or pressure-overloaded mice after ovary removal; however, estrogen replacement restored the effectiveness of sildenafil in these animals. In females, sildenafil-elicited myocardial PKG activity required estrogen, which stimulated tonic cardiomyocyte cGMP synthesis via an eNOS/soluble guanylate cyclase pathway. In contrast, eNOS activation, cGMP synthesis, and sildenafil efficacy were not estrogen dependent in male hearts. Estrogen and sildenafil had no impact on pressure-overloaded hearts from animals expressing dysfunctional PKGIα, indicating that PKGIα mediates antiremodeling effects. These results support the importance of sex differences in the use of PDE5 inhibitors for treating heart disease and the critical role of estrogen status when these agents are used in females.

AB - Inhibition of cGMP-specific phosphodiesterase 5 (PDE5) ameliorates pathological cardiac remodeling and has been gaining attention as a potential therapy for heart failure. Despite promising results in males, the efficacy of the PDE5 inhibitor sildenafil in female cardiac pathologies has not been determined and might be affected by estrogen levels, given the hormone's involvement in cGMP synthesis. Here, we determined that the heart-protective effect of sildenafil in female mice depends on the presence of estrogen via a mechanism that involves myocyte eNOS-dependent cGMP synthesis and the cGMP-dependent protein kinase Iα (PKGIα). Sildenafil treatment failed to exert antiremodeling properties in female pathological hearts from Gαq-overexpressing or pressure-overloaded mice after ovary removal; however, estrogen replacement restored the effectiveness of sildenafil in these animals. In females, sildenafil-elicited myocardial PKG activity required estrogen, which stimulated tonic cardiomyocyte cGMP synthesis via an eNOS/soluble guanylate cyclase pathway. In contrast, eNOS activation, cGMP synthesis, and sildenafil efficacy were not estrogen dependent in male hearts. Estrogen and sildenafil had no impact on pressure-overloaded hearts from animals expressing dysfunctional PKGIα, indicating that PKGIα mediates antiremodeling effects. These results support the importance of sex differences in the use of PDE5 inhibitors for treating heart disease and the critical role of estrogen status when these agents are used in females.

UR - http://www.scopus.com/inward/record.url?scp=84902185317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902185317&partnerID=8YFLogxK

U2 - 10.1172/JCI70731

DO - 10.1172/JCI70731

M3 - Article

VL - 124

SP - 2464

EP - 2471

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -